



PRESS RELEASE, July 1, 2019

SelectImmune Pharma strengthens its organization through the appointment of a Chief Medical Officer and Executive Chairman

SelectImmune Pharma has announced that the company has recruited Erik Sturegård as Chief Medical Officer (CMO). Erik Sturegård is an MD and has a PhD in clinical microbiology and many years of research experience in infectious diseases and antibiotics with previous senior positions in the healthcare sector. Erik Sturegård will take up his new position as CMO on July 1, 2019.

“I am very much looking forward to starting work with SelectImmune, which has an extremely exciting research portfolio. The global epidemic of antibiotic resistance means there is an enormous medical demand for new treatment alternatives,” says Erik Sturegård.

“Erik Sturegård’s expertise and experience is ideal for the company, and he will act as a driving force for clinical development,” says Fredrik Herslow, the company’s CEO.

SelectImmune Pharma has also announced the appointment of Catharina Svanborg as Executive Chairman with overall responsibility for the company’s operations. In this way, the Company is ensuring continuity and the necessary integration of research and drug development.

“I am delighted that the company is growing and is developing new drugs together with Erik Sturegård and the team,” says Catharina Svanborg, the company’s founder and Chairman of the Board.

For more information, contact

Catharina Svanborg +46 709 42 65 49
Catharina.Svanborg@med.lu.se

Fredrik Herslow, CEO SelectImmune Pharma, +46 705 91 15
44 Fredrik.Herslow@selectimmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The Company’s goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.